Zacks: Analysts Expect STAAR Surgical (STAA) Will Post Earnings of $0.03 Per Share

Equities research analysts expect STAAR Surgical (NASDAQ:STAA) to report earnings of $0.03 per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for STAAR Surgical’s earnings. STAAR Surgical posted earnings of $0.02 per share during the same quarter last year, which indicates a positive year over year growth rate of 50%. The firm is expected to report its next earnings report on Thursday, March 1st.

On average, analysts expect that STAAR Surgical will report full year earnings of $0.02 per share for the current year. For the next year, analysts expect that the company will post earnings of $0.19 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for STAAR Surgical.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, November 8th. The medical instruments supplier reported $0.02 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. STAAR Surgical had a negative net margin of 2.47% and a negative return on equity of 3.34%. The firm had revenue of $23.47 million during the quarter.

STAA has been the subject of several recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 target price on shares of STAAR Surgical in a research note on Sunday, October 8th. Zacks Investment Research downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Benchmark upped their target price on shares of STAAR Surgical from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, October 20th. Finally, BidaskClub downgraded shares of STAAR Surgical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. STAAR Surgical currently has a consensus rating of “Hold” and a consensus target price of $17.67.

In other STAAR Surgical news, VP Keith Holliday sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $16.65, for a total value of $99,900.00. Following the completion of the sale, the vice president now owns 45,969 shares of the company’s stock, valued at $765,383.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.60% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of STAA. Virtu KCG Holdings LLC bought a new stake in shares of STAAR Surgical during the second quarter worth $118,000. Prudential Financial Inc. bought a new stake in shares of STAAR Surgical during the third quarter worth $138,000. Citadel Advisors LLC bought a new stake in shares of STAAR Surgical during the third quarter worth $172,000. Goldman Sachs Group Inc. increased its position in shares of STAAR Surgical by 68.1% during the second quarter. Goldman Sachs Group Inc. now owns 19,073 shares of the medical instruments supplier’s stock worth $206,000 after acquiring an additional 7,729 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of STAAR Surgical during the second quarter worth $214,000. 77.85% of the stock is owned by institutional investors.

Shares of STAAR Surgical (NASDAQ STAA) opened at $16.45 on Friday. STAAR Surgical has a 12 month low of $8.95 and a 12 month high of $17.60. The company has a quick ratio of 1.72, a current ratio of 2.24 and a debt-to-equity ratio of 0.02. The company has a market cap of $650.40, a P/E ratio of -411.25 and a beta of 1.19.

ILLEGAL ACTIVITY NOTICE: This story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/28/zacks-analysts-expect-staar-surgical-staa-will-post-earnings-of-0-03-per-share.html.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply